We offer a competitive price for kilogram-scale manufacture, please contact us for a quotation for lipids and PEG-lipids for LNPs.
Reagents for Lipid Nanoparticles
Description
JenKem Technology provides large scale GMP manufacture of high purity lipids and PEG-lipids for Lipid Nanoparticles (LNPs) for commercial pharmaceutical applications and clinical trials. Please contact us for a quotation.
- Large scale GMP manufacture of conventional lipid products (cationic lipids, ionizable lipids, PEG lipids, phospholipids, helper lipids, SORT lipids, and others made-to-order)
- Innovative lipid products (JK-0315, JK-102, JK-0039, JK-0055, JK-0056) and LNP formulation development, such as Innovative 3-component LNPs and 5-component LNPs for selective organ targeting
- CDMO services for Lipid products (lipid process development, quality research, CDE/DMF application)
- LNP encapsulation services
- Analytical testing services (for LNP, RNA, LNP-RNA)
Example PEGs for LNPs:
M-DMG-2000 (Methoxy PEG Dimyristoyl-rac-glycerol, MW 2000)
M-DTDPA-2000 (Methoxy PEG Ditetradecylpropylamino, MW 2000)
M-EPOX-2000 (Methoxy PEG Epoxide, MW 2000)
M-GLC-2000 (Methoxy PEG Glycerol, MW 2000)
and many other PEG derivatives and intermediates
Example Small Molecule Reagents for LNPs:
JK-0315-CA (ALC-0315 analogue)
JK-102-CA (SM-102 analogue)
N, N-bistetradecylamine Ditetradecylamine (CAS no: 17361-44-3)
ALC-0159 (Sample for research purpose only, not for sale) (Methoxy PEG Ditetradecylacetamide, MW 2000)
ALC-0315 (Sample for research purpose only, not for sale) ([(4-hydroxybutyl)azanediyl]bis(hexane-6,1-diyl)bis(2-hexyldecanoate, CAS no.: 2036272-55-4)
SM-102 (Sample for research purpose only, not for sale) (Heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxO-6-(undecyloxy) hexyl) amino) octanoate), CAS no: 2089251-47-6)
LNPs drug delivery systems are commonly employed for nucleic acid drugs. LNPs are generally believed to
combine with the cell membrane through noncovalent affinity and absorbed by endocytosis. After being absorbed by the cell, the mRNA delivered by LNPs are released to the cytoplasm and express the target protein, escaping from the endocytosis. This technology has been adopted by pharmaceutical companies in the recent years for COVID-19 vaccine manufacture.
References:
- Jiang, F., et al., LNP-miR-155 cy5 Inhibitor Regulates the Copper Transporter via the β-Catenin/TCF4/SLC31A1 Signal for Colorectal Cancer Therapy, Molecular Pharmaceutics 2023 20 (8), 4138-4152
- Schoenmaker, Linde, et al., mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability, International Journal of Pharmaceutics 2021, 601
- Gu, T., et al., Intratumoural delivery of TRAIL mRNA induces colon cancer cell apoptosis, Biomedicine & Pharmacotherapy, 2024, V. 174. Keywords: mRNA; Lipid nanoparticles; apoptosis; death receptors; TRAIL; SM-102; DMG-PEG2000
- Wang, Q., et al., A pro-metastatic tRNA fragment drives aldolase A oligomerization to enhance aerobic glycolysis in lung adenocarcinoma, Cell Reports, 2024, V. 43, 8. Keywords: Methoxypoly (ethylene glycol)-ditetradecylacetamide (ALC-0159)
Founded in 2001 by experts in PEG synthesis and PEGylation, JenKem Technology specializes exclusively in the development and manufacturing of high quality polyethylene glycol (PEG) products and derivatives, co-polymers, lipids, fatty acid side chains, and related custom synthesis and PEGylation services. JenKem Technology is ISO 9001 and ISO 13485 certified, and adheres to ICH Q7 guidelines for GMP manufacture. The production of JenKem® PEGs is back-integrated to in-house polymerization from ethylene oxide, enabling facile traceability for regulated customers. JenKem Technology caters to the PEGylation needs of the pharmaceutical, biotechnology, medical device and diagnostics, and emerging chemical specialty markets, from laboratory scale through large commercial scale.